
doi: 10.2337/dc13-2738
pmid: 24804699
OBJECTIVE Low HDL cholesterol (HDL-C) and small HDL particle size may directly promote hyperglycemia. We evaluated associations of HDL-C, apolipoprotein A-I (apoA-I), and HDL-C/apoA-I with insulin secretion, insulin resistance, HbA1c, and long-term glycemic deterioration, reflected by initiation of pharmacologic glucose control. RESEARCH DESIGN AND METHODS The 5-year Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study followed 9,795 type 2 diabetic subjects. We calculated baseline associations of fasting HDL-C, apoA-I, and HDL-C/apoA-I with HbA1c and, in those not taking exogenous insulin (n = 8,271), with estimated β-cell function (homeostasis model assessment of β-cell function [HOMA-B]) and insulin resistance (HOMA-IR). Among the 2,608 subjects prescribed lifestyle only, Cox proportional hazards analysis evaluated associations of HDL-C, apoA-I, and HDL-C/apoA-I with subsequent initiation of oral hypoglycemic agents (OHAs) or insulin. RESULTS Adjusted for age and sex, baseline HDL-C, apoA-I, and HDL-C/apoA-I were inversely associated with HOMA-IR (r = −0.233, −0.134, and −0.230; all P < 0.001; n = 8,271) but not related to HbA1c (all P > 0.05; n = 9,795). ApoA-I was also inversely associated with HOMA-B (r = −0.063; P = 0.002; n = 8,271) adjusted for age, sex, and HOMA-IR. Prospectively, lower baseline HDL-C and HDL-C/apoA-I levels predicted greater uptake (per 1-SD lower: hazard ratio [HR] 1.13 [CI 1.07–1.19], P < 0.001; and HR 1.16 [CI 1.10–1.23], P < 0.001, respectively) and earlier uptake (median 12.9 and 24.0 months, respectively, for quartile 1 vs. quartile 4; both P < 0.01) of OHAs and insulin, with no difference in HbA1c thresholds for initiation (P = 0.87 and P = 0.81). Controlling for HOMA-IR and triglycerides lessened both associations, but HDL-C/apoA-I remained significant. CONCLUSIONS HDL-C, apoA-I, and HDL-C/apoA-I were associated with concurrent insulin resistance but not HbA1c. However, lower HDL-C and HDL-C/apoA-I predicted greater and earlier need for pharmacologic glucose control.
Blood Glucose, Male, HDL, 610, Fenofibrate, Insulin-Secreting Cells, 616, Diabetes Mellitus, Humans, Hypoglycemic Agents, Insulin, Aged, Apolipoprotein A-I, Cholesterol, HDL, Middle Aged, Prognosis, name=SDG 3 - Good Health and Well-being, Cholesterol, Cross-Sectional Studies, Treatment Outcome, Diabetes Mellitus, Type 2, Disease Progression, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, Female, Insulin Resistance, Type 2, Follow-Up Studies
Blood Glucose, Male, HDL, 610, Fenofibrate, Insulin-Secreting Cells, 616, Diabetes Mellitus, Humans, Hypoglycemic Agents, Insulin, Aged, Apolipoprotein A-I, Cholesterol, HDL, Middle Aged, Prognosis, name=SDG 3 - Good Health and Well-being, Cholesterol, Cross-Sectional Studies, Treatment Outcome, Diabetes Mellitus, Type 2, Disease Progression, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, Female, Insulin Resistance, Type 2, Follow-Up Studies
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 59 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
